This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Q-State Biosciences | |
|---|---|
| Name | Q-State Biosciences |
| Type | Private |
| Industry | Biotechnology |
| Founded | 2012 |
| Headquarters | San Diego, California |
| Key people | Not publicly linked |
| Products | Single-cell proteomics platforms |
Q-State Biosciences.
Q-State Biosciences is a biotechnology company focused on single-cell proteomics and spatial biology platforms used in translational research and drug discovery. The company develops instruments and reagents that integrate concepts from Stanford University, Massachusetts Institute of Technology, Scripps Research, Harvard University and University of California, San Diego laboratories to address challenges faced by researchers at institutions such as Broad Institute, Dana–Farber Cancer Institute, Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center.
Founded in the early 2010s amid breakthroughs at institutions like University of Oxford, Max Planck Society, Cold Spring Harbor Laboratory and Johns Hopkins University, the company emerged as part of a wave following advances from groups including Shai Shen-Orr-linked labs and teams associated with George Church. Early milestones were achieved as the firm collaborated with technology transfer offices at UC Berkeley, Imperial College London, Yale University and Rockefeller University to translate mass spectrometry and multiplexed imaging concepts into commercial platforms. The company’s trajectory intersected with commercialization patterns seen at startups spun out from Wellcome Trust-funded projects and partnerships reflecting the dynamics around Bill & Melinda Gates Foundation-supported translational initiatives.
Q-State’s platform suite builds on techniques related to single-cell proteomics, high-parameter cytometry and spatially resolved assays developed in tandem with methods pioneered at European Molecular Biology Laboratory, Stanford Medicine, ETH Zurich, Karolinska Institutet and University of Cambridge. Instrumentation combines optics and fluidics approaches akin to systems from Illumina, Thermo Fisher Scientific, BD Biosciences, Fluidigm and Cytiva while integrating computational pipelines influenced by algorithms from groups at Princeton University, University of Washington, Columbia University and University of Chicago. The platform supports workflows comparable to those used in studies published by teams at Broad Institute and laboratories associated with Fiona Watt and Eric Lander-era initiatives.
Researchers use Q-State technologies in cancer immunology, neuroscience, infectious disease and immunophenotyping studies conducted at centers such as Stanford Cancer Institute, Fred Hutchinson Cancer Center, Cleveland Clinic and UCSF Medical Center. Applications span translational projects similar to efforts at National Institutes of Health, collaborations with consortia like Human Cell Atlas contributors, and disease-focused research comparable to programs at National Cancer Institute, European Commission-funded networks, Wellcome Sanger Institute projects and vaccine research linked to Rockefeller Foundation-backed labs. Published use cases have appeared alongside studies from investigators affiliated with Karolinska Institutet, University College London, Boston Children’s Hospital and Salk Institute.
The company has engaged in partnerships with academic labs and commercial entities reflecting alliances seen between GlaxoSmithKline, Novartis, Pfizer, Roche and smaller instrument companies spun out of Stanford or MIT incubators. Strategic collaborations mirror arrangements common to tech transfer deals with universities such as University of Pennsylvania, Duke University, Cornell University and Michigan Medicine, and research agreements resembling those maintained by centers like European Molecular Biology Laboratory and Institut Pasteur. Industry partnerships also align with procurement relationships typical of clinical labs at Mayo Clinic, Johns Hopkins Hospital and Massachusetts General Hospital.
Early-stage financing for companies in this sector often involves investors and programs associated with Sequoia Capital, Andreessen Horowitz, ARCH Venture Partners, Flagship Pioneering and accelerator models seen at Y Combinator or IndieBio, with grant support patterned after awards from National Institutes of Health, European Research Council and philanthropic funders such as Chan Zuckerberg Initiative. Business development activities reflect typical routes to commercialization seen in exits and licensing deals involving firms like Illumina and Thermo Fisher Scientific and strategic collaborations similar to those executed by Genentech.
Work with human samples and translational data engages regulatory frameworks and ethical oversight involving groups and statutes commonly relevant to biotech, analogous to processes handled by U.S. Food and Drug Administration, European Medicines Agency, institutional review boards at University of California campuses, and ethics committees at hospitals like Johns Hopkins Hospital and Massachusetts General Hospital. Data management and patient privacy considerations parallel standards promoted by organizations such as World Health Organization and initiatives like Global Alliance for Genomics and Health.
Category:Biotechnology companies